Novavax receives CMA from European Commission

By The Science Advisory Board staff writers

December 22, 2021 -- Novavax announced that the European Commission (EC) has granted the company a conditional marketing authorization (CMA) for its Nuvaxovid COVID-19 vaccine for use in individuals age 18 and older. The CMA applicable in all 27 European Union member states.

According to the company, in two phase 3 clinical trials, NVX-CoV2373, Novavax's COVID-19 vaccine candidate, demonstrated high efficacy and an acceptable safety and tolerability profile. Novavax and the EC announced an advance purchase agreement in August 2021 in which the EC would purchase up to 200 million doses. The vaccine is also currently under review by multiple regulatory agencies worldwide.

Novavax completes submission of COVID vaccine candidate to WHO
Novavax has completed its rolling submission to the World Health Organization (WHO) for emergency use listing of NVX-CoV2373, its COVID-19 vaccine candidate.
Novavax submits COVID vaccine candidate to TGA
Novavax completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate in Australia.
Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...
Novavax posts positive preclinical results for flu/COVID-19 vaccine
Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter